NEW YORK – Pillar Biosciences said Wednesday that more of its OncoReveal next-generation sequencing panels will be offered by Illumina in an expansion of the companies’ existing partnership.
The deal includes the OncoReveal Essential MPN, Myeloid, Multi-Cancer with CNV and Fusion panel, and BRCA1 and BRCA2 plus CNV panel, which will be available as part of validated workflows on the MiSeq i100 sequencer launched last week.
The other Pillar oncology panels that will be sold by Illumina include the OncoReveal Core LBx, Essential LBx, and Fusion LBx for liquid biopsy, as well as the OncoReveal Multicancer RNA Fusion and Solid Tumor v2 for solid tumor profiling. These panels are for use on the Illumina MiSeq and NextSeq 550 instruments.
Financial and other terms of the deal were not disclosed.
"As part of Illumina's commitment to address our customers' total workflow, we are pleased to bring more oncology assays from Pillar Biosciences into our product lineup," Angela Ryan, VP of product management at Illumina, said in a statement.
Illumina and Pillar began partnering on NGS-based diagnostics in 2017 and signed a global distribution agreement last year.